Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis

Journal of Vascular Surgery

Volumn 28, Issue 5, 1998, Pages 848-854

  Downing, L J ^a   Strieter, R M ^a   Kadell, A M ^a   Wilke, C A ^a   Greenfield, L J ^a   Wakefield, T W ^a  

^a THCC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; INFERIOR CAVA VEIN; INFLAMMATION; MORPHOMETRICS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VEIN LIGATION; VEIN THROMBOSIS; VEIN WALL;

EID: 0031744024     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0741-5214(98)70060-6     Document Type: Article

References (28)

1. GP Clagett FA Anderson J Heit Prevention of venous thromboembolism Chest 108 Suppl 1995 S312 S334
2. LJ Downing RM Strieter AM Kadell Neutrophils are the initial cell type identified in deep venous thrombosis induced vein wall inflammation ASAIO J 42 1996 M677 M682
3. TW Wakefield RM Strieter CA Wilke Venous thrombosis-associated inflammation and attenuation with neutralizing antibodies to cytokines and adhesion molecules Arterioscl Thromb Vasc Biol 15 1995 258 268
4. LJ Downing TW Wakefield RM Strieter Anti-P-selectin antibody decreases inflammation and thrombus formation in venous thrombosis J Vasc Surg 25 1997 816 828
5. J. Fareed Heparin, its fractions, fragments, and derivatives Semin Thromb Hemost 11 1985 1 9
6. U. Abildguard Tissue factor pathway inhibition and heparin DA Lane I Bjork U Lindahl Heparin and related polysaccharides. 1992 : Plenum Press New York 199 204
7. RL. Bick Antithrombotic therapy RL Bick Hematology: Clinical and laboratory practice. 1993 : Mosby St. Louis 1603 1631
8. H-P Ekre Y Naparastek O Lider Anti-inflammatory effects of heparin and its derivatives. Inhibition of complement and of lymphocyte migration DA Lane I Bjork U Lindahl Heparin and related polysaccharides. 1992 : Plenum Press New York 329 340
9. M Saliba Jr RJ. Saliba Heparin in burns: Dose related and dose dependent effects Thrombosis et Diathesis Haemorrhagica 33 1975 113 123
10. ML Larsen U Abildgaard AN Teien K. Gjesdal Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238) Thromb Res 13 1978 285 288
11. TP Green DE Johnson RP Marchessault CW. Gatto Transvascular flux and tissue accrual of Evans blue: Effects of endotoxin and histamine J Lab Clin Med 111 1988 173 183
12. O Linderkamp T Mader O Butenandt KP. Riegel Plasma volume estimation in severely ill infants and children using a simplified Evans blue method Eur J Pediatr 125 1977 135 141
13. A Saria JM. Lundberg Evans blue fluorescence: Quantitative and morphological evaluation of vascular permeability in animal tissue J Neurosci Methods 8 1983 41 49
14. LM Colletti SL Kunkel A Walz MD Burdick RG Kunkel CA Wilke Chemokine expression during hepatic ischemia/reperfusion-induced lung injury in the rat J Clin Invest 95 1995 134 141
15. PW Majerus GJ Broze Jr JP Miletich Anticoagulant, thrombolytic and antiplatelet drugs 9th ed Goodman Gilman The pharmacological basis of therapeutics. 1995 : Pergamon Press New York 1341 1359
16. EG Vairel H Bouty-Boye F Toulemonde C Doutremepuich Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis Thromb Res 30 1983 219 224
17. LJ Smith KL Schaible RG Fessler Examination of the utility of the rat as an animal model for human anticoagulation Haemostasis 17 1987 206 210
18. AB Grossat TE Spiro J Beynon Enoxaparin, a low molecular-weight heparin suppresses prothrombin activation more effectively than unfractionated heparin in patients treated for venous thromboembolism Thrombosis Research 86 1997 349 354
19. L Leung K Saigo G. Grant Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effect of histidine-rich glycoprotein Blood 73 1989 177 184
20. R Abbate AM Gori PA Modesti Heparin, monocytes, and procoagulant activity Haemostasis 20 Suppl 1 1990 98 100
21. J. Dawes Interactions of heparins in the vascular environment Haemostasis 23 Suppl 1 1993 212 219
22. MA Blajchman E Young FA. Ofosu Effects of unfractionated heparin, dermatan sulfate, and low molecular weight heparin on vessel wall permeability in rabbits Annals of the New York Academy of Sciences 556 1989 245 254
23. RL Hoover R Rosenberg W Haering MJ. Karnovsky Inhibition of rat arterial smooth muscle cell proliferation by heparin. II: In-vitro studies Circ Res 47 1980 578 583
24. JG Wright JC Kerr CR Valeri RW. Hobson Heparin decrease ischemia-reperfusion injury in isolated canine gracilis model Arch Surg 123 1988 470 472
25. M Klagsbrun A. Baird A dual receptor system is required for basic fibroblast growth factor activity Cell 67 1991 229 231
26. JM Weiler RE Edens RT Linhardt DP. Kapelanski Heparin and modified heparin inhibit complement activation in vivo J Immunol 148 1992 3210 3215
27. RJ Linhardt KG Rice YS Kim JD Engelken JM. Weiler Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro J Biol Chem 263 1988 13090 13096
28. RM Nelson O Cecconi WG Roberts A Aruffo RJ Lindhart MP. Bevilicqua Heparin oligosaccharide bind L- and P-selectin and inhibit acute inflammation Blood 82 1993 3253 3258